Answers are grounded in this paper and cite their sources.
A phase I study assessed the safety and immunogenicity of the naked DNA Omicron BA.2 booster vaccine, Alveavax-v1.2, in 130 South African adults previously vaccinated with Janssen Ad26.COV2.S. Participants received varying doses intradermally or subcutaneously, or a Janssen booster as a control. The vaccine was well tolerated, with mild to moderate adverse events across all groups and no serious events linked to vaccination. However, the antibody response was modest, with no significant increases in Omicron BA.2 titers observed in any group. The vaccine remained shelf stable for over six months at room temperature.
No takes yet. Share an insight, caveat, or question.
Schons et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: